AAV Gene Therapy

Using a hollowed-out virus to deliver a working gene.

Adeno-associated virus (AAV) is the workhorse delivery vehicle of gene therapy: a harmless virus shell, emptied of its own genes and repacked with a therapeutic one. Different AAV 'serotypes' home to different tissues (tropism), letting developers aim at liver, eye, muscle or CNS.

The constraints are real — a small cargo limit, immune responses to the capsid, and the cost of one-time dosing. But for single-gene problems and for delivering longevity payloads (klotho, FGF21, even reprogramming factors), it's the leading route to durable, sometimes one-shot, effect.

How it works in depth

Adeno-associated virus (AAV) gene therapy uses a hollowed-out, non-replicating virus as a delivery vehicle, or vector. Scientists strip out the viral genome and package a therapeutic transgene inside the protein shell, called the capsid. Once infused, the AAV docks onto target cells and ferries its cargo into the nucleus, where the new gene mostly persists as a stable episome (a circular fragment that sits outside the chromosomes) rather than integrating into the host DNA. The cell then reads the gene and produces a working protein the patient lacks. Because the DNA does not replicate with cell division, durability is strongest in long-lived, slowly dividing tissue such as neurons, muscle, retina, and liver. Different AAV serotypes (AAV9, AAVrh74, AAV8 and others) have different tissue preferences, which is why developers match the capsid and delivery route to the disease.

Where the field is in 2025-2026

The field is at an inflection point. As of 2024-2025 the FDA had approved several AAV products, including PTC Therapeutics' Kebilidi for AADC deficiency in November 2024, the first AAV therapy delivered directly into the brain. Yet the dominant narrative is one of retrenchment. Big pharma has pulled back: reportedly Pfizer, Takeda, Vertex, and Biogen (which discontinued its AAV capsid programs in September 2025) all stepped away. The central debates are immunogenicity (pre-existing neutralizing antibodies exclude many patients and largely block redosing) and high-dose toxicity. Most starkly, the FDA in 2025 investigated patient deaths from acute liver failure tied to Sarepta's Elevidys and the shared AAVrh74 serotype, added a boxed warning, paused some shipments, and revoked the platform technology designation. This has intensified work on next-generation engineered capsids and "lower and slower" dosing.

Leading programs & players

Commercially, Zolgensma (Novartis, AAV9, spinal muscular atrophy) remains the leader at an estimated ~$1.24B in 2025, while Elevidys (Sarepta/Roche, Duchenne) reportedly generated roughly $820M in 2024 before its safety setbacks. Hemophilia programs disappointed: Hemgenix (CSL Behring, hemophilia B) saw minimal uptake, and BioMarin reportedly withdrew Roctavian (hemophilia A) in late 2025 after weak sales. Other players include uniQure, Ultragenyx (UX111 for Sanfilippo type A, with a 2025 FDA review), Regenxbio, and Solid Biosciences. The market outlook is mixed: estimates put gene therapy revenue in the multi-billion range with long-term growth projected, but the near-term mood is cautious, hinging on whether engineered capsids, better immunosuppression, and manufacturing economics can make AAV safer, redosable, and affordable.

FAQ

Is AAV gene therapy permanent or do you need repeat doses?

It is designed as a one-time treatment. The delivered gene usually persists as an episome outside the chromosomes, so it can last years in long-lived cells, but it can fade in dividing tissue. Redosing is difficult because patients develop neutralizing antibodies to the AAV capsid after the first dose.

Is AAV gene therapy safe?

Approved AAV therapies are generally used in serious diseases with monitoring, but high systemic doses carry real risks, including liver injury, thrombocytopenia, and rare deaths. In 2025 the FDA added a boxed warning to Sarepta's Elevidys after fatal acute liver failure cases. Safety is dose- and serotype-dependent and remains an active concern.

Why does AAV gene therapy cost so much?

These are one-time treatments for rare diseases with complex viral manufacturing and small patient populations, so prices reach into the millions per patient. Zolgensma, for example, has carried a list price around $2.1M, which has fueled debate over reimbursement and value-based pricing.

What is the difference between AAV serotypes like AAV9 and AAVrh74?

Serotypes are AAV variants whose capsids target different tissues. AAV9 crosses into the central nervous system and is used in Zolgensma for SMA, while AAVrh74 targets muscle and is used in Elevidys for Duchenne. Choosing the serotype helps direct the therapy to the right organ.

Companies working on AAV Gene Therapy

Explore the interactive landscapes →